What type of study is this?

October 2, 2025Open Access

Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

View Full Paper

Ask AI

Bookmark

Treatment with nelitolimod and pembrolizumab resulted in significant tumor shrinkage.
Patients with PD-L1 positive tumors showed a greater percentage change in tumor size compared to others.
The findings support the efficacy of PD-L1 targeted therapy in combination with immunotherapy.
Further investigations will be essential to validate these promising results in larger cohorts.

Implication

Phase 2 trial shows greater tumor shrinkage in PD-L1 positive melanoma patients treated with nelitolimod and pembrolizumab.

Abstract

Figure S3 shows best percentage changes from baseline in target lesion size, grouped by PD-L1 status, for patients treated with nelitolimod 8 mg plus pembrolizumab 200 mg. The plot highlights greater tumor shrinkage in patients with PD-L1–positive tumors

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ribas et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219d8 https://doi.org/10.1158/1078-0432.30255668

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 trial shows greater tumor shrinkage in PD-L1 positive melanoma patients treated with nelitolimod and pembrolizumab.

Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading